Fig. 1: Study flowchart of identifying eligible COVID-19 patients and nirmatrelvir/ritonavir users for inclusion in the two target trial emulations. | Nature Communications

Fig. 1: Study flowchart of identifying eligible COVID-19 patients and nirmatrelvir/ritonavir users for inclusion in the two target trial emulations.

From: Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation

Fig. 1

Adult nirmatrelvir/ritonavir users with confirmed SARS-CoV-2 infection diagnosis during the study period were identified from the data source. Following the application of study inclusion and exclusion criteria, 87,070 nirmatrelvir/ritonavir users were included for the mortality or hospitalization analysis and 9669 nirmatrelvir/ritonavir users were included for the viral burden rebound analysis.

Back to article page